SECURITIES ISSUANCE AGREEMENTSecurities Issuance Agreement • January 14th, 2015 • Ziopharm Oncology Inc • Services-specialty outpatient facilities, nec • Texas
Contract Type FiledJanuary 14th, 2015 Company Industry JurisdictionTHIS SECURITIES ISSUANCE AGREEMENT (the “Agreement”), dated as of January 13, 2015, by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the “Issuer”), the University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center, an agency of the State of Texas (“MD Anderson”). Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.4.
Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies Combined Technologies to Leapfrog...Exclusive Licensing Agreement • January 14th, 2015 • Ziopharm Oncology Inc • Services-specialty outpatient facilities, nec
Contract Type FiledJanuary 14th, 2015 Company IndustryGERMANTOWN, Md., BOSTON, Ma., and HOUSTON, Tx., January 13, 2015 – Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ:ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 14th, 2015 • Ziopharm Oncology Inc • Services-specialty outpatient facilities, nec • Texas
Contract Type FiledJanuary 14th, 2015 Company Industry JurisdictionTHIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of January 13, 2015, by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the “Issuer”), and the University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center, an agency of the State of Texas (“MD Anderson”), and shall become effective as of the Closing (as defined in the Issuance Agreement, defined below).